SP
Syncona Partners LLP
Venture CapitalActiveSyncona Partners LLP is a healthcare company focused on investing in and building global leaders in life science.
London, United KingdomFounded 2012
24
Investments
4
Exits
$1.2B
AUM
16.7%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Syncona Partners LLP.
Investment Thesis & Strategy
Syncona Partners LLP invests in various stages of life science companies, specifically focusing on building global leaders in biotech and healthcare.
Investment Activity
Deals per year over the last 7 years
1
20153
20160
20170
20182
20191
20205
2021Portfolio Companies
Selected investments from their portfolio of 24 companies
A
Anagenesis
Biotech · Series A, 2021
F
Fourthline
Fintech · Series A, 2021
C
Cellares
Biotech · Series B, 2021
Q
Quell Therapeutics
Biotech · Series A, 2021
O
O Mass Therapeutics
Biotech · Series A, 2021
P
Purespring Therapeutics
Biotech · Series A, 2020
A
Achilles Therapeutics
Biotech · Series A, 2019
E
Enara Bio
Biotech · Series A, 2019
G
Gyroscope Therapeutics
Biotech · Series A, 2016
F
Freeline Therapeutics
Biotech · Series A, 2016
N
Nightstar Therapeutics
Biotech · Series A, 2016
A
Autolus Therapeutics
Biotech · Series A, 2015
Notable Exits
CompanyTypeYearValue / Acquirer
Achilles TherapeuticsIPO2022$175M
Gyroscope TherapeuticsAcquisition2022$1.48B
Freeline TherapeuticsIPO2021$150M
Nightstar TherapeuticsAcquisition2019$855M
Frequently Asked Questions
Syncona Partners LLP focuses on Series A, Series B, Series C+ stage investments.